NCCN Evidence Blocks

View More View Less
  • 1 Presented by Robert W. Carlson, MD, NCCN, Fort Washington, Pennsylvania, and Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Restricted access

NCCN has developed a series of Evidence Blocks: graphics that provide ratings for each recommended treatment regimen in terms of efficacy, toxicity, quality and consistency of the supporting data, and affordability. The NCCN Evidence Blocks are currently available in 10 tumor types within the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). At a glance, patients and providers can understand how a given treatment was assessed by the NCCN Guidelines Panel and get a sense of how a given treatment may match individual needs and preferences. Robert W. Carlson, MD, CEO of NCCN, described the reasoning behind this new feature and how the tool is used, and Eric Jonasch, MD, Professor of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, and Vice Chair of the NCCN Kidney Cancer Panel, described its applicability in the management of metastatic renal cell carcinoma.

Correspondence: Robert W. Carlson, MD, NCCN, 275 Commerce Drive, Suite 300, Fort Washington, PA 19034. E-mail: carlson@nccn.org; Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030. E-mail: ejonasch@mdanderson.org
  • 1.

    Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115124.

  • 2.

    Sternberg CN, Davis ID, Mardiak J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:10611068.

    • Search Google Scholar
    • Export Citation
  • 3.

    Motzer RJ, Hutson TE, McCann L. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;370:17691770.

  • 4.

    Hudes G, Carducci M, Tomczak P. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:22712281.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 940 429 15
PDF Downloads 184 112 6
EPUB Downloads 0 0 0